Overview

Phase I/II Clinical Study of Decitabine Combined With TQB2450 Injection or Decitabine + Anlotinib Combined With TQB2450 Injection in the Treatment of PD-1 Monoclonal Antibody-resistant Digestive System Tumors

Status:
Not yet recruiting

Trial end date:
2020-12-01

Target enrollment:

Participant gender:

Summary

This clinical study focused on patients with digestive system tumors resistant to PD-1 inhibitors, and explored the reversal resistance of epigenetic drugs (decitabine) and TKI drugs (anlotinib) in this part of patients.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Peking University

Treatments:

Decitabine